Membrane PKC-beta 2 protein expression predicts for poor response to chemotherapy and survival in patients with diffuse large B-cell lymphoma

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Annals of Hematology

• Publication date

  2006-07-08

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s00277-006-0144-yPMID 16830142
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Expression of PKC-beta or cyclin D2 predicts for inferior survival in diffuse large B-cell lymphoma

  2005cited by this paper
• Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.

  2004cited by this paper
• Protein kinase C family functions in B-cell activation.

  2004cited by this paper
• Protein kinase C and beyond

  2004cited by this paper
• Building an outcome predictor model for diffuse large B-cell lymphoma.

  2004cited by this paper
• Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL).

  2003cited by this paper
• A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma

  2003cited by this paper
• Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma.

  2003cited by this paper
• Protein Kinase C β Controls Nuclear Factor κB Activation in B Cells Through Selective Regulation of the IκB Kinase α

  2002cited by this paper
• Protein Kinase C (cid:2) Controls Nuclear Factor (cid:3) B Activation in B Cells Through Selective Regulation of the I (cid:3) B Kinase (cid:4)

  2002cited by this paper
• Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning

  2002cited by this paper
• PKC-beta controls I kappa B kinase lipid raft recruitment and activation in response to BCR signaling.

  2002cited by this paper
• The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.

  2002cited by this paper
• Intercellular Transfer and Supramolecular Organization of Human Leukocyte Antigen C at Inhibitory Natural Killer Cell Immune Synapses 〉

  2001cited by this paper
• Diffuse large cell lymphoma.

  2001cited by this paper
• Constitutive Nuclear Factor κB Activity Is Required for Survival of Activated B Cell–like Diffuse Large B Cell Lymphoma Cells

  2001cited by this paper
• Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

  2000cited by this paper
• Diffuse large-cell lymphoma.

  2000cited by this paper
• Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.

  1999cited by this paper
• A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group.

  1994cited by this paper
• A predictive model for aggressive non-Hodgkin's lymphoma.

  1993cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper
• Regression Models and Life-Tables

  year unknowncited by this paper

• Oxidative Stress and ROS Link Diabetes and Cancer

  2024cites this paper
• Protective Effect of Ebselen on Ischemia-reperfusion Injury in Epigastric Skin Flaps in Rats

  2022cites this paper
• Protein Kinase C (PKC) Isozymes as Diagnostic and Prognostic Biomarkers and Therapeutic Targets for Cancer

  2022cites this paper
• Calcium-dependent signalling in B-cell lymphomas

  2021cites this paper
• Role of Oncogenic Protein Kinase C-iota in Melanoma Progression; A Study Based on Atypical Protein Kinase-C Inhibitors

  2019cites this paper
• PKC : An Ambiguous Target in Cancer Therapy

  2019cites this paper
• Transient cerebral ischemia/reperfusion-induced acute lung injury in rats associated with protein kinase C alpha expression.

  2018cites this paper
• Classical Protein Kinase C: a novel kinase target in breast cancer

  2018cites this paper
• Alternative pre-mRNA splicing leads to potential biomarkers in diffuse large B-cell lymphoma - a systematic review.

  2016influential citation
• Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL.

  2015cites this paper
• Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review

  2015cites this paper
• Identification of pharmacogenomic markers of clinical efficacy in a dose-dense therapy regimen (R-CHOP14) in diffuse large B-cell lymphoma

  2014cites this paper
• Protein kinase C and cancer: what we know and what we do not

  2014cites this paper
• Protein Kinase C (PKC) Isozymes and Cancer

  2014cites this paper
• 1 Protein kinase C ( PKC ) as a drug target in chronic lymphocytic leukemia

  2014cites this paper
• Biomarkers of diffuse large B-cell lymphoma: impact on diagnosis, treatment, and prognosis

  2013cites this paper
• Carbon tetrachloride-induced hepatic injury through formation of oxidized diacylglycerol and activation of the PKC/NF-κB pathway

  2013cites this paper
• Protein kinase C (PKC) as a drug target in chronic lymphocytic leukemia

  2013cites this paper
• Prognostic impact of protein kinase C β II expression in R-CHOP-treated diffuse large B-cell lymphoma patients

  2010cites this paper
• PKC and the Control of Apoptosis

  2010cites this paper
• PROGNOSTIC MOLECULAR FACTORS AND ALGORITHMS IN DIFFUSE LARGE B-CELL LYMPHOMA

  2010cites this paper
• Emerging therapies for B-cell non-Hodgkin lymphoma

  2009cites this paper
• Protein Profiling of Plasma Membranes Defines Aberrant Signaling Pathways in Mantle Cell Lymphoma*

  2009cites this paper
• Protein kinase C-beta II expression in diffuse large B-cell lymphoma predicts for inferior outcome of anthracycline-based chemotherapy with and without rituximab

  2009cites this paper
• Protein kinase C beta in malignant pleural mesothelioma

  2008cites this paper
• Wealth of opportunity - the C1 domain as a target for drug development.

  2008cites this paper
• B-cell receptor signaling in chronic lymphocytic leukemia cells is regulated by overexpressed active protein kinase CbetaII.

  2007cites this paper
• Protein expression and cellular localization in two prognostic subgroups of diffuse large B-cell lymphoma: Higher expression of ZAP70 and PKC-β II in the non-germinal center group and poor survival in patients deficient in nuclear PTEN

  2007cites this paper
• Retrospective analysis of protein kinase C-beta (PKC-β) expression in lymphoid malignancies and its association with survival in diffuse large B-cell lymphomas

  2007cites this paper
• B-cell receptor signaling in chronic lymphocytic leukemia cells is regulated by overexpressed active protein kinase C II

  2006cites this paper